Spots Global Cancer Trial Database for Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma
Official Title: Phase II Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma
Study ID: NCT01219751
Conditions
Interventions
Study Description
Brief Summary: To evaluate the efficacy and safety of sunitinib in non-clear cell type renal cell carcinoma with the exception of pure sarcomatoid carcinoma and collecting duct carcinoma
Detailed Description: There have been no standard treatment in non-clear cell renal cell carcinoma. Retrospective studies showed sunitinib or sorafenib might be active in non-clear cell renal cell carcinoma, especially papillary type and chromophobe type. This study is to evaluate efficacy and safety of sunitinib in this group of patients.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Asan Medical Center, Seoul, , Korea, Republic of
Contact Details
Name: Jae-Lyun Lee, MD, PhD
Affiliation: Asan Medical Center
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
